Vivanti, an award-Winning Life-Science Marketing Agency is set to transform the UK pharmaceutical and life sciences sectors, bringing a unique blend of medical expertise, strategic marketing, and AI-driven innovations – tailored specifically for the Life Sciences industry.
Originating from a strong 14-year heritage in Europe as a marketing powerhouse, Vivanti now expands its influence across the entire pharma value chain by enhancing how pharmaceutical and biotech companies engage with their audiences, bringing innovative solutions and a transformative/bold approach to the industry.
Whilst already serving some of the most renowned pharmaceutical companies in the world, offering a unique blend of marketing, medical, creative, and technical expertise – the company’s aim is to stand out in a competitive space by seamlessly integrating these elements to set new standards and redefine industry benchmarks.
Vivanti’s expansion includes a focus on innovative AI-driven solutions designed to streamline processes and improve operational efficiency. The business believes early adopters of its innovative solutions will gain a significant competitive edge, with research showing that those who embrace new technologies early can achieve up to 70% improved operational efficiency compared to peers who are slower to adapt1.
This comprehensive approach enables Vivanti to meet all client needs in a single, integrated service offering, providing Innovative Marketing and Efficiency Solutions for Life Science Companies:
1. AI & Digital Transformation:
Vivanti leverages their AI-assistants and automation to enhance operational efficiency, including a Commercial Optimisation Suite (COSMART) of tools like AVA for training simulations and NBA (Next Best Action) to boost sales force effectiveness. Additionally, Rep CoPilot offers in-depth sales force performance analysis, and MedDossier (due to be launched in October 2024) streamlines the automation of clinical study reports and CTDs, marking significant strides in their digital transformation.
2. High-impact Marketing:
Vivanti is well-versed in the complexities and regulations of the RX market. The marketing experts offer a comprehensive suite of services specifically tailored to address the unique challenges and needs of the pharmaceutical industry. Vivanti excels in delivering 360-degree strategy consulting and planning, with a strong focus on executing multichannel and omnichannel campaigns, toensure effective marketing reaches and engages audiences across all platforms.
The group’s comprehensive review and planning services include analysing past and current campaigns, reviewing marketing and medical content, mapping customer journeys, selecting appropriate channels, topics and formats, and developing product positioning and messaging strategies aligned with the client’s objectives.
Central to Vivanti’s data-driven approach is NINA, a Marketing Mix Modelling tool that guarantees every campaign is effective and measurable. Vivanti creates integrated marketing strategies to engage customers through digital solutions like webinars, virtual events, SEO, and social media, as well as traditional methods such as event management, printed materials, and patient awareness campaigns.
3. Content Creation:
Content is King – Vivanti merges graphic design, technology, and medical expertise to excel in healthcare communication. Services range from creating visually compelling accurate healthcare detailing materials and clinical cases, to developing HCP portals and engaging life science videos. These include medical explainer videos, KOL interviews, and patient stories.
Vivanti’s approach to content excellence is rigorous, focusing on medical areas such as oncology, rare diseases, neurology, and infectious diseases, among others. Edutainment and gamification is a key component of the business offering, with the Vivanti team integrating immersive technologies like VR/AR to enhance learning and engagement. Recognising that content is king, Vivanti upholds high standards within its in-house medical expertise, producing content that is both precise and tailored to meet the needs of healthcare professionals, evidenced by studies showing high reliance on accurate and easy-to-use medical information.
Vivanti provides exceptional service and support, ensuring that clients can effectively navigate the complexities of the pharmaceutical landscape while maximising their potential for success.
The diverse team at Vivanti includes fintech specialists who bring invaluable AI expertise to the pharmaceutical sector, ensuring that clients remain ahead in a rapidly evolving landscape.
With a portfolio boasting over 5150 successful projects across 200 clients, Vivanti is committed to driving the future of pharma marketing and is planning a number of significant and exciting new product launches in Q4 this year – including an AI Assistant breakthrough to bolster sales training and support ROI. Further details on this breakthrough NPD will be announced to coincide with the 14th Annual Sales Force Effectiveness and Digital Marketing in Pharma Summit in Berlin on 16th October 2024 – where the team will be showcasing the solution to industry leaders.
Marina Hickson, Managing Director of Vivanti comments, “At Vivanti we are your partner in Life Science Transformation. As an industry, pharma has traditionally been slower to adopt AI than some other sectors – around 11.5% in healthcare as opposed to almost a third (29.2%) in IT and telecoms2. However, now that we’re able to show real benefits and impact across businesses – from the drug development cycle to the sales chain – interest is growing rapidly. Our team comes with experience across the pharma, Digital Health and Fintech markets which we believe is vital to deliver robust programmes that are adaptive to the nuances of this highly regulated sector, as well as providing reliable and evidence-based results. Our door is open (both virtually and IRL!) and we’re ready to chat!”.
For more information visit www.vivanti.eu or follow us on LinkedIn @vivanti
—
Citation:
- Deloitte. (2024). Unleash AI’s potential: Measuring the return from pharmaceutical innovation. Retrieved from https://www2.deloitte.com/content/dam/Deloitte/it/Documents/life-sciences-health-care/deloitte-measuring-return-from-pharmaceutical-innovation-2024.pdf
- Primary data from Forbes Advisor was taken from a sample of 2,000 adults, representative of the UK population. It was commissioned by Forbes Advisor and conducted by market research company Opinium. Data was collected in May 2023.
[4] https://www.scilife.io/blog/ai-pharma-innovation-challenges
